PRINCETON, N.J., May 5 /PRNewswire-FirstCall/ -- Derma Sciences (OTC Bulletin Board: DSCI), a manufacturer and marketer of advanced wound care products, today announced that it intended to voluntarily delist its common stock, $0.01 par value, from the defunct Boston Stock Exchange and that it would file Form 25 with the Securities and Exchange Commission on or about May 15, 2009 to effect this delisting.
Ed Quilty, CEO of Derma Sciences, noted that, "In October, 2007 Nasdaq acquired the Boston Stock Exchange and immediately terminated the exchange's trading activities. Thus, the delisting is merely a formality and should have no impact whatsoever on the trading of our common stock."
About Derma Sciences
Derma Sciences is a global manufacturer and marketer of advanced wound care products. Its key product, MEDIHONEY(R), is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was the focus of a positive large-scale randomized controlled trial on leg ulcers. Derma's recently FDA cleared BIOGUARD(TM) Barrier Dressing is the Company's latest new product entrant into the $14 billion global wound care market. The barrier technology was licensed from Quick-Med Technologies, Inc. in Q1 of 2007. Derma also has in development DSC127, a novel angiotensin analog for accelerated wound healing and scar reduction. DSC127 was licensed from the University of Southern California in Q4 of 2007. Patient enrollment for a Phase II study began in Q4 of 2008. Results from this study are expected to be submitted to the FDA in Q2 of 2010.
For more information about Derma Sciences, Inc., visit http://www.dermasciences.com/.
Forward-looking Statements
Statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements which may be made in this release or which are otherwise made by or on behalf of the Company. Factors which may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements Include but are not limited to, those discussed in the Company's filings with the Securities and Exchange Commission.
Contact: Derma Sciences, Inc. Edward J. Quilty Chairman and CEO equilty@dermasciences.com (609) 514-4744 Allen & Caron Inc Rudy Barrio (US Investors) r.barrio@allencaron.com (212) 691-8087 Brian Kennedy (Media) brian@allencaron.com (212) 691-8087
Derma Sciences, Inc.
CONTACT: Edward J. Quilty, Chairman and CEO of Derma Sciences, Inc.,
+1-609-514-4744, equilty@dermasciences.com; or US Investors, Rudy Barrio,
+1-212-691-8087, r.barrio@allencaron.com, or Media, Brian Kennedy,
+1-212-691-8087, brian@allencaron.com, both of Allen & Caron Inc, for Derma
Sciences, Inc.
Web Site: http://www.dermasciences.com/
